publication date: Dec. 19, 2010
In this issue:
Phase 0 trials signal FDA’s new reliance on biomarkers for drug development.
NCI faces $32 million budget cut in FY 2006; NIH tells grantees to expect 2.35 percent reduction in award funds.
NCI establishes new Program Project grant guidelines.
Chemotherapy pioneer Howard Skipper dead; his work with leukemia cells in mice led to development of combination therapies.
Download (PDF 2.9MB)
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.